Search clinical trials for: X4P-001

Total 4169 results

X4 Pharmaceuticals

Active, not recruiting

A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

Neutropenia

United States
X4 Pharmaceuticals

Completed

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Waldenstrom's Macroglobulinemia

United States, Greece
X4 Pharmaceuticals

Not yet recruiting

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Neutropenia
X4 Pharmaceuticals

Completed

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

WHIM Syndrome

Australia, United States
Abbisko Therapeutics Co, Ltd

Enrolling by invitation

A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Triple Negative Breast Cancer

China
X4 Pharmaceuticals
Covance

Terminated

A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

Healthy

United States
X4 Pharmaceuticals

Active, not recruiting

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

WHIM Syndrome

United States, Denmark, Australia, Austria, France, Hungary, Israel, Italy, Korea, Republic of, Netherlands, Russian Federation, Spain, Turkey
University of Pennsylvania

Terminated

Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection

Recurrent Clostridium Difficile Infection

United States
Revibe Technologies

Completed

Assessing a Wearable Digital Therapy for Youth With ADHD

ADHD

United States
University of Pennsylvania

Terminated

Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)

Severe Clostridium Difficile Infection | Severe-Complicated/Fulminant Clostridium Difficile Infection

United States
University of Manitoba
Canadian Institutes of Health Research (CIHR); Canadian Cancer Society (CCS); The Canadian Collaborative for Childhood Cannabinoid Therapeutics

Not yet recruiting

CANnabinoids in Pediatric ONCology (CAN-PONC)

Cancer | Childhood Cancer
EyeGene Inc.
Novotech (Australia) Pty Limited

Completed

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers

Prevention of Herpes Zoster (HZ)

Australia
Patagonia Pharmaceuticals, LLC

Completed

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

Congenital Ichthyosis

United States
X4 Pharmaceuticals

Completed

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma (X4P-001-MELA)

Melanoma

United States
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Subjects With Asthma

Asthma
PMG Pharm Co., Ltd

Completed

Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs

Arthritis

Korea, Republic of
Kukje Pharma

Completed

[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001

Dry Eye Syndromes

Korea, Republic of
EGEN, Inc.

Terminated

Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer

Ovarian Neoplasms

United States
X4 Pharmaceuticals

Completed

Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States, Korea, Republic of
DermBiont, Inc.

Suspended

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis

Onychomycosis

United States
X4 Pharmaceuticals

Terminated

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States
DermBiont, Inc.

Active, not recruiting

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis

Tinea Pedis

United States
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Healthy Subjects

Influenza A H3N2

United Kingdom
Pfizer

Completed

A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers.

Smoking | Vaccines

Canada
National Cancer Institute (NCI)

Completed

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

Head and Neck Cancer | Head and Neck Neoplasms

United States
EGEN, Inc.

Completed

Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer

Ovarian Neoplasms

United States
101 Therapeutics

Active, not recruiting

Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects

Virus Diseases | COVID-19 | Infectious Disease | Glucocorticoids Toxicity

India
Alaunos Therapeutics

Completed

Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma

Melanoma

United States
Dr. August Wolff GmbH & Co. KG Arzneimittel
Parexel

Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of WOL071-007 in Atopic Dermatitis Patients

Dermatitis, Atopic

Germany
TR Therapeutics

Completed

Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

Wounds

United States
NewG Lab Pharma

Active, not recruiting

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Fibrolamellar Carcinoma

Korea, Republic of
Antengene Corporation

Terminated

A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (MATCH)

Relapsed/Refractory Diffuse Large B-cell Lymphoma

China
EyeGene Inc.
Novotech (Australia) Pty Limited

Active, not recruiting

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers

COVID-19 Vaccine

Australia
Claris Biotherapeutics, Inc.

Recruiting

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

Corneal Scar

United States
Cryonove Pharma
CEISO; Dermatech; Sefako Makgatho Health Sciences University

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots.

Solar Lentigo | Post-inflammatory Hyperpigmentation | Senile Lentigo

South Africa
Cryonove Pharma
CEISO; Dermatech; LTD HEALTH

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots

Lentigo Solar

Georgia
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
IntegoGen, LLC

Withdrawn

Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
4Moving Biotech

Completed

Safety, Tolerability and Pharmacokinetics of Intra-articular (IA) Single Ascending Dose of 4P-004 in Patient With Kellgren and Lawrence Grade 2 to 4 Osteoarthritic (OA) Knee (LASARE)

Knee Osteoarthritis

Belgium
Claris Biotherapeutics, Inc.

Recruiting

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

Neurotrophic Keratitis

United States, Canada
University of Aarhus
Odense University Hospital; Oslo University Hospital; Rigshospitalet, Denmark; Hvidovre... and other collaborators

Completed

Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV (TITAN)

HIV-1-infection

Norway, Denmark, United States, Australia
Toll Biotech Co. Ltd. (Beijing)

Recruiting

A Study of Single and Multiple Oral Doses of TollB-001

Rheumatoid Arthritis

China
JANSSEN Alzheimer Immunotherapy Research & Development...

Terminated

AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Heartseed Inc.

Recruiting

A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study) (LAPiS)

Heart Failure | Ischemic Heart Disease

Japan
National Cancer Institute (NCI)

Completed

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines

Prostatic Neoplasms | Prostatic Cancer

United States
Azura Ophthalmics
Syneos Health; Cliantha Research

Completed

A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)

Dry Eye | Meibomian Gland Dysfunction

Canada, Australia, New Zealand
Frontera Therapeutics

Recruiting

Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy

Biallelic RPE65 Mutation-associated Retinal Dystrophy

China
Immunophotonics, Inc.

Recruiting

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (INJECTABL-1)

Soft Tissue Sarcoma | Nonsmall Cell Lung Cancer | Metastatic Solid Tumor | Colon Cancer

France, United Kingdom, United States, Germany, Switzerland
Vasomune Therapeutics, Inc.

Recruiting

Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

Pneumonia, Viral | Pneumonia | Acute Respiratory Distress Syndrome | Respiratory Infection | COVID-19 Acute Respiratory Distress Syndrome | Viral or Bacterial Infections

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

Attention Deficit Hyperactivity Disorder

United States

Search clinical trials for: X4P-001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations